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Background/Purpose: The aim of this study was to identify key characteristics of disease progression
through investigation of the association of radiographic progression over two years with baseline Joint
Space Width (JSW), KellgreneLawrence (KL) grade, Western Ontario and McMaster Universities Arthritis
Index (WOMAC) pain, Joint Space Narrowing (JSN), and BMI.
Methods: Data from 2206 subjects (4390 knees) were combined for this post-hoc analysis of two ran-
domized, double-blind, multi-center, placebo-controlled phase III trials (NCT00486434 and
NCT00704847) that evaluated the efﬁcacy and safety of 2-years treatment with oral salmon calcitonin of
subjects with painful knee osteoarthritis (OA).
Results: There was a clear positive and signiﬁcant correlation between KL grade and WOMAC pain and
total WOMAC, albeit the variance in pain measures was from min-to-max for all KL categories,
emphasizing the heterogeneity of this patient population and pain perception. 32% of target knees did
not progress, and only 51% had changes over minimum signiﬁcant change (MSC). BMI, KL-Score and
WOMAC pain was diagnostic, but only KL-score and pain had prognostic value, albeit pain in a non-linear
manner.
Conclusion: These data clearly describe signiﬁcant associations between KL grade, JSW, pain and BMI in
patients with symptomatic knee OA. KL grade, BMI and WOMAC pain were diagnostically associated with
OA based on JSW but only KL-score and pain in a non-linier fashion was prognostic. 50% of patients did
not progress more than MSC, highlighting the importance for identiﬁcation of structural progressors and
the phenotypes associated with these. These results suggest that disease phenotypes, rather than disease
status, are responsible for disease progression.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is themost common form of arthritis1e3, One
of themost pressing concerns inmedical science is the need to treat
the right patients with the right medicine. However, in light of the
current absence of structure modifying treatments for OA, an evenM.A. Karsdal, Nordic Biosci-
rk. Tel: 45-44-54-77-70; Fax:
arsdal).
ternational. Published by Elsevier Lmore pressing concern is the need to identify the optimal patient
population in which to test a given treatment.
The exact etiology of OA is still relatively unknown, but factors
known to be involved include risk factors such as age4, obesity4e7,
genetic predisposition4,8, joint mal-alignment9, acute joint
injury4,10 and reduced gender hormone levels in relation to
menopause2. These multi-factorial disease etiologies present a
challenge to instituting Personalized Health Care (PHC) in OA11,
namely the prospect of providing the right patient with the right
drug; the multi-factorial nature of the disease also presents a
challenge regarding selection of patient subtypes for targeted drugtd. All rights reserved.
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subtypes would greatly facilitate the development of structure
modifying treatments; however, this supposition needs to be
tested.
Prediction of OA progression is one of the most important topics
in the OA ﬁeld. As reported from the Osteoarthritis Initiative (OAI),
only 4% of OA patients without symptomatic OA and up to 14% with
incident OA progress over a 1 year period12. This suggests that OA
disease activity may vary between periods of inertia and periods of
faster progression. Consequently, it is essential to identify the
drivers of disease progression in order to develop effective
interventions.
OA may have different phenotypes13. The ﬁeld in particular
has focused on the articular cartilage phenotype14 and more
recently, a bone driven cartilage progression phenotype15.
However, a degree of inﬂammation is now recognized as being a
central part of the OA pathology16,17. While inﬂammation may
not be the initiator of disease, it may at some point be the driver
of disease progression18. As multiple tissues are affected, it seems
quite unlikely that all OA patients would be effectively treated
with the exact same interventions. It is plausible that the failure,
in part, of numerous phase II/III OA clinical trial failures, such as;
iNOS19, bisphosphonates20, and calcitonin15,21 and the partial
failure of strontium ranelate22, has been due to the failure to
identify patient subpopulations which matched the pharmaco-
dynamics of the drug11.
Oral salmon calcitonin (sCT), recently failed to meet study
endpoints in two randomized phase III trials21,23. The combined
information of the two phase III clinical studies of sCT may provide
needed insights into the means of identifying subpopulations of OA
patients who would be ideally suited for particular interventions.
The aim of this post-hoc analysis to study baseline characteristics,
such as Joint Space Width (JSW), Western Ontario and McMaster
Universities Arthritis Index (WOMAC) pain and function scores, of
patients with knee OA from two randomized, multicenter, placebo-
controlled phase III trials, to identify different phenotypes associ-
ated with progression.
Methods
Subjects and methods
This is the ﬁrst post-hoc analysis and was performed using
pooled baseline data from 2206 patients participating in two ran-
domized, multicenter, placebo-controlled phase III trials evaluating
efﬁcacy and safety of an oral formulation of sCT vs placebo in pa-
tients with painful OA of the knee (www.clinicaltrials.gov regis-
tration number NCT00486434 and NCT00704847)49. The main
inclusion criteria for the target knee were 1: American College of
Rheumatology (ACR) OA criteria24, 2: KellgreneLawrence (KL) In-
dex: Grades 2 or 3 of the medial tibio-femoral joint, 3: American
Rheumatism Association (ARA) functional class I, II, or III25, 4: a JSW
of 2.0 mm of the medial tibio-femoral joint (measured from knee
radiographs), and 5: signiﬁcant pain, deﬁned as a WOMAC subscale
(ﬁve questions) result of 150 mm. In CSMC021C2301, patients
with pain <150 mm but with aWOMAC function score of510 mm
were allowed inclusion. For this analysis, data from both the target
knee and the contra-lateral knee were included for all patients,
yielding data from 4390 knees. As stated, this population was
originally selected to have painful OA in the target knee however;
present data includes baseline data from both the target knee and
the contra-lateral knee, thus enriching the selected populationwith
a wider range of knee phenotypes.Radiographic evaluation
Radiographs by X-rays were performed to assess KL grade and to
measure JSW, using a standardized, quality-controlled method. The
X-ray images were read centrally by the same radiologist.
Pain evaluation
Knee OA pain was evaluated using the WOMAC index pain
subscale. Patients answered each of the ﬁve questions on a 100mm
scale where 0 is no pain at all, and 100 mm is the worst imaginable
pain. The total score is the sum of all ﬁve results. In the trials that
used for this scale, a total WOMAC-assessed pain of 150 mmwas
an inclusion criterion, however in CSMC021C2301, patients with
pain <150mm but with aWOMAC function score of510mmwere
also included.
Statistical methods
The WOMAC pain sub-score, stiffness subs-core, and function
sub-score consisted of the sum of the ﬁve pain questions, two stiff-
ness questions, and 17 function questions, respectively. Joint space
narrowing (JSN) over the 2-year study period was calculated as the
difference between the JSW at baseline minus the JSW at month 24.
In the assessment of predictors for JSW or the 2-year JSN, quartile
group of BMI at baseline (Q1: below 25.6 kg/m2; Q2: 25.6e28.4 kg/
m2; Q3: 28.4e31.8 kg/m2; Q4: 31.8 kg/m2 or above) and quartile
group ofWOMAC pain (Q1: 184mmor below, Q2: 185e231mm, Q3:
232e289 mm, Q4: 290 or above) in target knee at baseline was
calculated. The lowest WOMAC pain quartile group was additionally
divided into two groups of WOMAC pain from 0 to 149 mm (Q1a)
and 150e184mm (Q1b) in order to take the inclusion criteria of pain
of target knee into account when including both target and contra-
lateral knee in the model analysis. A random effect mixed model
was used for assessment of predictors of the JSW at baseline and the
2-year JSN. The initial mixed model of JSW included JSW as the
dependent variable, and the independent variables of KL grade (KL 0,
1, 2, 3, and 4), knee (target, contra-lateral knee), gender, age group
(65 years,65 years), BMI in quartiles (Q1, Q2, Q3, and Q4), WOMAC
pain in quartiles (quartile Q1a, Q1b, Q2, Q3, and Q4), and study as
ﬁxed effects as well as all pair-wise interaction terms. Subject was
included as a random effect to take the clustering effect into account
that each subject contributed with two knees. The mixedmodel was
stepwise reduced by excluding the least signiﬁcant term until all
remaining terms were signiﬁcant. A similar initial mixed model was
used for modeling of JSN. This model included data from the placebo
group with JSW change as the dependent variable, and the inde-
pendent variables of KL grade (KL 1, 2 and 3), baseline JSW group
(1e2mm, 2mm or above), knee (target, contra-lateral knee), gender,
age group (<65 years, 65 years), BMI in quartiles, WOMAC pain
(0e149 mm, 150e184 mm, 185e231 mm, 232e289 mm,
290e500 mm), and study as ﬁxed effects as well as all pair-wise
interaction terms. Subject was included as a random effect, and the
mixed model was stepwise reduced as described above. A term in
themodelswas considered signiﬁcant if the P-valuewas less than 5%.
All statistical calculations were performed using the SAS software
package.
Results
Baseline patient characteristics
Baseline patient demographics are shown in Table I.
Table I
Demographic characteristics
Parameter CSMC021C2301
N ¼ 1176
CSMC021C2302
N ¼ 1030
All N ¼ 2206
Gender e n (%)
Male 372 (31.6) 404 (39.2) 776 (35.2)
Female 804 (68.4) 626 (60.8) 1,430 (64.8)
Age (years)
Mean (SD) 64.5 (6.63) 64.3 (6.93) 64.4 (6.77)
Median (min,
max)
64.3 (50, 80) 63.7 (51, 80) 64.2 (50, 80)
Age group (years) e n (%)
<65 614 (52.2) 580 (56.3) 1194 (54.1)
65 562 (47.8) 450 (43.7) 1012 (45.9)
Race e n (%)
Caucasian 1071 (91.1) 873 (84.8) 1944 (88.1)
Asian 104 (8.8) 144 (14.0) 248 (11.2)
Other 1 (0.1) 13 (1.3) 14 (0.6)
BMI (kg/m2)
Mean (SD) 29.0 (4.70) 29.0 (5.21) 29.0 (4.95)
Median (min,
max)
28.4 (18.1, 57.7) 28.3 (17.3, 50.3) 28.4 (17.3, 57.7)
KL grade e n (%)
Target knee
KL 2 1032 (87.8) 809 (78.5) 1841 (83.5)
KL 3 144 (12.2) 221 (21.5) 365 (16.5)
Contra-lateral knee
Not applicable 12 (1.0) 10 (1.0) 22 (1.0)
KL 0 36 (3.1) 56 (5.4) 92 (4.2)
KL 1 230 (19.6) 186 (18.1) 416 (18.9)
KL 2 644 (54.8) 458 (44.5) 1102 (50.0)
KL 3 222 (18.9) 293 (28.4) 515 (23.3)
KL 4 32 (2.7) 27 (2.6) 59 (2.7)
JSW (mm)
Target knee
Mean (SD) 3.37 (0.96) 3.47 (1.02) 3.42 (0.99)
Median (min,
max)
3.3 (1.8, 6.7) 3.5 (1.8, 7.3) 3.4 (1.8, 7.3)
Contra-lateral knee
Mean (SD) 3.31 (1.37) 3.33 (1.48) 3.32 (1.42)
Median (min,
max)
3.5 (0.0, 8.0) 3.5 (0.0, 8.0) 3.5 (0.0, 8.0)
WOMAC pain (mm)
Target knee
Mean (SD) 237 (76) 247 (70) 242 (73)
Median (min,
max)
229 (40, 500) 235 (117, 495) 232 (40, 500)
Contra-lateral knee
Mean (SD) 179 (110) 184 (114) 181 (112)
Median (min,
max)
173 (0, 500) 183 (0, 500) 178 (0, 500)
Table II
Spearman correlation (Rho) of baseline characteristics and baseline JSW
JSW KL grade at
baseline
BMI Age WOMAC
pain
KL
Target knee 2e3 Rho 0.122 0.06 0.08 0.28
P-
value
<0.0001 0.005 0.0004 <0.0001
n 2206 2206 2205 2206
Contra-lateral
knee
0 to 4 Rho 0.14 0.11 0.20 0.37
P-
value
<0.0001 <0.0001 <0.0001 <0.0001
n 2184 2184 2094 2184
Contra-lateral
knee
0e1 Rho 0.04 0.10 0.06 e
P-
value
0.33 0.03 0.19
n 508 508 492
Contra-lateral
knee
2e3 Rho 0.15 0.07 0.20 e
P-
value
<0.0001 0.008 <0.0001
n 1617 1617 1550
Contra-lateral
knee
4 Rho 0.21 0.20 0.01 e
P-
value
0.12 0.13 0.94
n 59 59 52
Table III
JSW (mm) in KL grade groups
KL grade N (knees) Mean JSW STD SEM Range of JSW
All 4390 3.37 1.22 0.018 0e8.0
KL 0 92 3.92 0.82 0.086 2.4e6.4
KL 1 416 3.74 0.83 0.041 1.1e6.6
KL 2 2943 3.60 0.98 0.018 0e7.7
KL 3 880 2.49 1.48 0.050 0e7.9
KL 4 59 1.49 2.52 0.328 0e8.0
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Baseline JSW was signiﬁcantly correlated with BMI, age,
WOMAC pain and KL grade (Table II) for both the target and contra-
lateral knees. Interestingly, these correlations were only signiﬁcant
in the subset of contra-lateral knees that were KL grades 2e3,
which represented the largest subgroup by severity grade.
Association between KL grade and mean JSW
Mean baseline JSW in all knees (target and contra-lateral)
stratiﬁed by KL grade is shown in Table III. The mean JSW did not
differ greatly between KL grades 0 to 2 knees, but was markedly
reduced in KL 3 knees and further reduced in KL 4 knees. There was
high inter-patient variation, but a highly statistical correlation be-
tween KL grade and JSW, in the target knee 0.29 P < 0.0001 and
contra-lateral knee 0.39, P < 0.0001. In the KL 2 group of 2943
knees, a mean JSW of 3.60 mm with a standard deviation of
±0.98 mm was observed, while the mean JSW of KL grade 3 knees
was 2.42 mm ± 1.48 mm (Table III). The distribution of JSW as afunction of KL grades is shown in Fig. 1(A); this also shows that the
patient disease characteristic of JSW was comparable in the two
studies, CSMC021C2301 and CSMC021C2302. As a possible result of
the inclusion criteria, for KL grade 3 knees, the mean JSW of the
signal knee was signiﬁcantly higher than that of the non-signal
knee [Fig. 1(B)].
Association between KL grade and WOMAC score
Themean impact on pain and function of a KL grade 4 severity of
OA (1034 ± 323 mm) was roughly double that of a KL grade 0 knee
without radiographic OA (475 ± 390 mm) [Fig. 1(C)]. As observed
for both pain and JSW, for all KL grades except KL grade 4 (with a
minimum reported function score of 270 mm), there was a high
level of variation in function scores ranging from no impairment
(0 mm) to nearly the highest possible level of impairment.
Mean baseline WOMAC pain-score (ﬁve questions) in all knees
(target and contra-lateral) stratiﬁed by KL grade is given in Table IV.
Mean OA pain was correlated with KL grades in a near-linear
fashion (Table IV and Fig. 1(D)). Mean pain ranged from 135 mm
(95% conﬁdence interval (CI) of mean 112e157mm)at KL grade 0, to
285 mm (95% CI of mean: 254e315 mm)in KL grade 4 knees. The
level of pain experienced by OA patients, regardless of KL grade,
varied greatly as reﬂected by scores ranging from absolutely pain
free (0 mm) to the worst imaginable pain (500 mm) for all KL
grades, except for the KL 4 groupwherein the lowest reported value
was 40mm (Table IV). Although the mean level of pain in the target
knees was similar for KL grades 2 and 3, the KL grade 2 target knees
were associated with more pain than contra-lateral knees, whereas
the KL grade 3 target knees had similar mean pain scores to KL
grade 3 contra-lateral knees [Fig. 1(C)].
Fig. 1. Baseline JSW, pain and function, stratiﬁed by KL Grade. A) Mean JSW in osteoarthritic knees graded KL 0e4 in the total cohort (N ¼ 4390), and the two individual trials,
CSMC021C2301 (N ¼ 2352) and CSMC021C2302 (N ¼ 2060). B) JSW in the target (N ¼ 2206) vs the contra-lateral contra-lateral knees (N ¼ 2184) C) Mean WOMAC pain (N ¼ 4299)
and function (N ¼ 4278) scores in the total cohort. D) Mean total WOMAC pain in the target (N ¼ 2205) and contra-lateral (N ¼ 2094). Error bars are 95% conﬁdence limit of mean.
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gender and WOMAC pain
The assessment of JSW measured at baseline revealed a statis-
tically highly signiﬁcant correlation of JSW and KL-score
(P < 0.0001, Fig. 2). This effect was different between the two
studies (P ¼ 0.05, Fig. 2(A)), target knee and contra-lateral knee
(P < 0.0001, Fig. 2(B)), gender-dependent (P ¼ 0.004, Fig. 2(C)), and
dependent on WOMAC pain group (P < 0.001, Fig. 2(D)).
Overall only a minor decrease in JSW was observed in knees
with KL 1 and KL 2 as compared to KL 0, whereas a major decrease
in JSW was observed in KL 3 knees of 1.57 mm (95% CI:
1.20e1.93 mm) and 1.27 mm (95% CI: 0.93e1.61 mm) in
CSMC021C2301 and CSMC021C0212302; and KL grade 4 knees of
2.08 mm (95% CI: 1.52e2.64 mm) and 1.84 mm (95% CI:
1.22e2.46 mm) [Fig. 2(A)].
Comparison of JSW in target knee vs contra-lateral knee showed
that the JSW was comparable in knees with KL grade 2, but the
target knees with KL grade 3 had a higher JSW of 0.48 mm (95% CI:
0.36e0.61 mm; P < 0.001) in comparison with the contra-lateral
knee [Fig. 2(B)]. In general females seemed to have slightly lower
JSW of 0.10 mme0.67 mm than males as observed in KL grade
groups of KL0, KL1, KL2, and KL4 [Fig. 2(C)].
There was a signiﬁcant association between WOMAC pain and
JSW (P < 0.0001) and this effect was KL-score dependent
(P ¼ 0.001). In KL grade 0, 1, and 2 knees there seemed to be noTable IV
WOMAC pain (mm) in KL grade groups
KL grade N (knees) Mean pain score STD SEM Range pain scores
All 4316 212 99 1.5 0e500
KL 0 88 135 105 11.2 0e410
KL 1 404 157 104 5.2 0e430
KL 2 2904 211 94 1.7 0e500
KL 3 851 245 94 3.2 0e500
KL 4 52 285 109 15.2 40e463association between JSW and WOMAC pain score. In KL grade 3
knees therewas a gradual decrease in JSWwith increasingWOMAC
pain with a difference of 0.37 mm (95% CI: 0.14 to 0.61; P ¼ 0.002)
between those with highest pain as compared to those with lowest
pain. A more dramatic effect was observed for the KL grade 4 knees
[Fig. 2(D)].
There was statistically highly signiﬁcant effect of BMI with a
decrease in JSWwith increasing BMI (P < 0.0001). The effect size in
difference in JSW between subjects in the highest quartile (Q4)
having BMI of 31.8 kg/m2 or above in comparison with subjects in
the lowest quartile (Q1) having a BMI below 25.6 kg/m2 was a
decrease of 0.31mm (95% CI: 0.21e0.42mm; P < 0.0001) [Fig. 2(E)].
Age in the age groups of below 65 years as compared with 65
years or above did not in itself contribute statistically signiﬁcant to
JSW (P ¼ 0.23).
Association between KL grade, WOMAC and progression (JSN)
Table VI shows the distribution of subjects classiﬁed according
to their degree of JSN at the 2-year end point. The classiﬁcation of
minimum statistically signiﬁcant JSN of 0.26 mm is based on an
estimation of the imprecision of a single JSW reading of 2.8%26 and
an overall mean JSW of 3.3e3.4 mm at study start. The number of
progressors knees was similar in the target and contra-lateral
knees. Only 32% of total knees in the target knee progressed
measured as delta JSN <0, and only 49% progressed above the
minimal signiﬁcant change (Table V).
Overall, including all knees of the placebo group, the mean JSN
progression (mean ± SEM) was 0.286 ± 0.016mm during the 2-year
trial period. Further sub-group analysis showed that over the
2 years, mean ± SEM knee JSN progression was 0.320 ± 0.024 mm
for the target knees in comparison with 0.250 ± 0.022 mm for the
contra-lateral knees (P < 0.01). The correlations between BMI,
WOMAC pain, JSW, KL grade and JSN after 2 years are given in
Table VI. KL gradewas signiﬁcantly associated with JSN progression
(P < 0.05) in the target, but not the contra-lateral knee.
Fig. 2. Baseline JSW from mixed model analysis showing the JSW (LS means ± 95% CI) according to KL-score and study (A), KL grade and target knee (B), KL-score and gender (C),
BMI in quartiles (E), and KL-score and WOMAC pain (D). Totally 4299 knees had complete data and were included in the model.
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included the target knees and contra-lateral knees with KL grades
of 1, 2, and 3 and a minimum JSW at baseline of 1 mm or above
comprising in total 1475 knees. It was found that KL grade at
baseline was a statistically signiﬁcant predictor for JSN (P ¼ 0.03)
with highest JSN in KL grade group 3 and almost comparable JSN in
KL grade group 1 and 2 (Fig. 3). As compared with KL grade 1, a KL
grade of 2 was associated with an increased JSN of 0.02 mm (95%
CI: 0.09e0.14 mm) and a KL grade of 3 was associated with an
increased JSN of 0.14 mm (95% CI: 0.00e0.28 mm).
WOMAC painwas statistically signiﬁcantly (P ¼ 0.02) associated
with JSN with the pattern of relationship showing an inverted U-
shape pattern (Fig. 3). The highest JSN was observed in theWOMAC
pain quartiles of Q2 and Q3 and lowest JSN in Q1a and Q4. As
compared with Q1a (low pain ranging from 0 to 149) mm, mod-
erate pain in Q2 (185e231 mm) and Q3 (232e289 mm) was asso-
ciated with an increased JSN of 0.13 mm (95% CI: 0.03e0.23 mm)
and 0.15 mm (95% CI: 0.05e0.25 mm) whereas higher pain in Q4 of
290 mm or above was associated with an increase of 0.05 mm (95%
CI: 0.05e0.16 mm) only.
There was a statistically signiﬁcant minor difference between
studies of 0.08 mm (95% CI. 0.00e0.16 mm; P ¼ 0.04) lower JSN in
CSMC021C2301 as compared with CSMC021C2302. The lower JSN
in CSMC021C2301 was caused by lower JSN in females than males
in CSMC021C2301 (P < 0.0001). There was no signiﬁcant difference
in JSN between genders in CSMC0212302 (P ¼ 0.82), and the pa-
rameters of baseline JSW group (1e2 mm, 2 mm or above), knee
(target, contra-lateral knee), and age group (<65 years, 65 years)
were not statistically signiﬁcant associated with JSN. Also BMI in
quartiles was not signiﬁcantly associated with JSN (P ¼ 0.23)
although there might be a trend of higher JSN the higher the BMI
quartile (Fig. 3).
Discussion
To the best of our knowledge, these combined data represent
the largest randomized clinical trial (RCT) dataset available for posthoc analysis of symptomatic knee OA patients at risk of progression.
The main ﬁndings were;
1. 51% of patients in the target, and 55% of the contra-lateral knee
did not progress above the calculated minimum signiﬁcant
change (MSC). 32% and 36% respectively, did not progress, JSN
change more <0 mm. This clearly suggests that selection criteria
can be further reﬁned to better enrich for progressors.
2. Progression in relation to pain was non-linear. The Q2eQ3
quartile progressed faster than the Q1 and Q4 quartiles. This
suggests that OA symptoms are a risk factor for progression,
however that severe pain does not necessarily confer greater
risk of progression and that different phenotypes of pain/pro-
gressors may exist.
3. Pain scores correlated better with JSW in contra-lateral vs target
knees, suggesting different pain reporting or perception in
target vs contra-lateral.
4. BMI, Age and WOMAC pain were diagnostically strongly asso-
ciated with a diagnosis of OA based on JSW, but only KL grade
and WOMAC pain were prognostic, i.e., for predicting JSN.
5. The risk of progression was associated with baseline radio-
graphic status e such as KL grade; a stronger association was
observed for progression when an OA clinical descriptive
phenotype included pain, and KL grade in combination.
The discussion is divided into “diagnostic & burden of disease
measures” and “prognostic measures”, according to the BIPED
criteria27.
Diagnostic and burden of disease measures
At baseline, mean JSWwas consistent across the two trials, both
overall and comparing subgroupswith identical KL grades.WOMAC
pain, BMI, age and KL grade were highly associated with JSW
(Burden of disease), as diagnostic markers, which corroborates
numerous ﬁndings28,29. As KL grade is partly confounded by JSW
assessment this correlation to two measure of burden of disease
Table V
Distribution according to degree of JSN at year 2 in KL grade groups
JSN <0 mm 0e0.26 mm 0.26e0.5 mm 0.5e1.0 mm 1.0e2.0 mm >¼2 mm
Target knee
All 32% (256) 19% (152) 16% (130) 19% (147) 11% (86) 3% (20)
KL 2 34% (223) 19% (128) 16% (107) 18% (118) 10% (68) 2% (13)
KL 3 25% (33) 18% (24) 17% (23) 22% (29) 13% (18) 5% (7)
Contra-lateral knee
All 774 36% (278) 19% (148) 19% (149) 16% (122) 8% (62) 2% (15)
KL 0 35% (9) 19% (5) 27% (7) 15% (4) 4% (1) 0% (0)
KL 1 33% (42) 23% (29) 23% (29) 13% (17) 7% (9) 2% (2)
KL 2 35% (149) 20% (85) 19% (79) 15% (64) 9% (37) 1% (6)
KL 3 37% (68) 15% (28) 17% (32) 18% (33) 8% (15) 4% (7)
KL 4 59% (10) 6% (1) 12% (2) 24% (4) 0% (0) 0% (0)
Table VI
Spearman correlation (Rho) of baseline characteristics and JSW change at year 2
BMI WOMAC pain JSW KL grade
JSW change in
target knee
Rho 0.03 0.02 0.04 0.09
P-value 0.39 0.57 0.31 0.01
n 791 791 791 791
JSW change in
contra-lateral knee
Rho 0.01 0.09 0.07 0.03
P-value 0.71 0.01 0.04 0.36
n 774 751 774 774
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similar in KL grades 0e2 with a sharp drop in JSW in KL 3 and a
further drop in KL 4. It is noteworthy that overall, no signiﬁcant
reduction occurred in JSW across KL grade 0e2, indicating minor
changes in cartilage thickness at these radiographic severity stages.
The signiﬁcant drop in JSW from KL grade 2 to 3 is expected, and is
likely to be a direct reﬂection of the emphasis on the element of JSN
in the classiﬁcation of KL grades 3 and 4. For KL grade 2, the target
knee had a lower JSW compared to the contra-lateral knee
(3.32 ± 0.03 mmvs 3.42 ± 0.02 mm, respectively, in alignment with
the lower mean pain observed in the contra-lateral knee. For KL
grade 3 this was different, which for the major part may be due to
the inclusion criteria emphasizing on JSW >2 mm for target knees.
Further analysis showed a stronger correlation between JSW and
pain levels regardless of KL grade contra-lateral vs target, empha-
sizing the large variation between burden of disease and pain
levels, and the difference between pain and reporting of pain in
target vs contra-lateral knees. The wide ranges and high standard
deviations of observed JSW, regardless of KL group, is remarkable,
and underscores the heterogeneity of this disease population inFig. 3. JSN predictors from mixed model analysis showing the JSN at the 2-year endpoint in
in quartiles (B; Q1 below 25.6 kg/m2; Q2 25.6e28.4 kg/m2, Q3 28.4e31.8 kg/m2, Q4 31.8 kg/
Q2 185e231 mm, Q3 232e289 mm, Q4 290e500 mm). Totally 1457 knees in KL 1, 2, an 3which neither pain, JSW nor KL grade alone seem to be good de-
scriptors of disease severity.
Pain and the relation to joint damage is a much debated area in
the OA ﬁeld30e36, as pain and joint damage are not necessarily
correlated. As expected, in relation to the selection criteria, subjects
reported less mean (± SEM) WOMAC pain in the contra-lateral
knees than in the target knee (181 ± 2.5 mm vs 242 ± 1.6 mm),
but interestingly, a slightly lower mean JSW (3.32 ± 0.03 mm vs
3.42 ± 0.02 mm) was observed, possibly due to the inclusion
criteria. For knees with KL grade 2, considerably less pain was re-
ported in the contra-lateral knees compared to target and for KL
grade 3 knees; the pain was similar in the target and contra-lateral
knees (161 ± 3.2 vs 240 ± 1.7 mm. This may suggests that pain
perception differences in relation to JSW in the target knee
compared to the contra-lateral knee, possibly due to active
inﬂammation and over reporting of pain in the target knees.
Prognostic measures
BMI and age were not statistically signiﬁcant associated with
JSN progression; these results are in accord with previous ﬁndings,
which suggested that subchondral bone texture by fractal signature
analysis was the best predictor of radiographic progression28,29. Of
great interest was the fact that pain37e41 was associated with pro-
gression, albeit not in a linear manner. The Q2eQ3 pain quartile
progressed the fastest. Many factors may explain this, possibly due
to less physical activity or active inﬂammation, but more likely to
the nature of this different OA population compared to other
studies, consisting exclusively of KL grade 2e3 with symptomatic
OA pain, who constitute the treatment-population of OA studies.
Most likely other parameters of activity may later be assessed bythe placebo group (LS means ± 95% CI) according to baseline KL-score (A), baseline BMI
m2 or above), and baseline WOMAC pain group (C; Q1a 0e149 mm, Q1b 150e184 mm,
had complete data and were included in the model.
M.A. Karsdal et al. / Osteoarthritis and Cartilage 23 (2015) 550e558556serological biomarkers42 and contribute to the understanding of
pain, pathological processes and progression.
BMI was not a risk factor for progression albeit highly diag-
nostic. This may be consequent to the small effect size of BMI on
JSW, and as the follow-time was only 2 years compared to long
term demographic studies, the time to research signiﬁcant was not
present, although a trend was observed. Further analysis may focus
on the fat distribution which has been shown to be very important
in the cardiovascular ﬁeld for predicting acute myocardial infarc-
tion (AMI), as central fat was demonstrated to be a risk factor while
peripheral fat was protective43,44
The demographic and radiographic data used in the current
analysis suggests that a combination of KL grade, with pain and BMI
may in part be important together with other modalities for
identiﬁcation of the OA phenotype associated with progression of
OA.
General considerations
A randomized clinical study may be different compared to
epidemiological studies inmanyaspects, in particular consequent to
stringent inclusion criteria for signal knees. Investigator initiated
studies often aim to recruit a high number subjects for investigating
prevalence and incidence (an all-comer strategy), whereas clinical
trials aim to recruit knee OA patients with speciﬁed characteristics
which allow for identiﬁcation of progression and thus enabling
identiﬁcation of treatment efﬁcacy. Examples of large-scale popu-
lation studies that focus on OA are the OAI50, CHECK51, MOST52, RSI-
III53, Chingford54 and the JoCo55 studies. Two additional differences
are important to consider (1) Clinical studies focus on speciﬁc target
joints in contrast to many of the population based studies and (2)
clinical trials tend to include older patients with overweight of
women (60e70%)19,20,22. Consequently to these considerations, this
largest combined RCT for prevalent symptomatic OA population is
clearly different from the large epidemiologic cohort studies, and
may be used as a database for improved design of future OA RCTs.
The average JSN progression of 0.159 mm/year in the current study
was comparable to the progression in the prevalent OA patient
population reported for CHECK, OAI and the JoCoOA37,45e47.
Conclusion
There is an urgent medical need to further identify disease
phenotypes, preferably by simple technologies, to allow for patient
selection of bone, cartilage and inﬂammation driven OA pheno-
types and matching the best intervention to each individual
phenotype11. Hopefully, our results, together with lessons learned
from other ﬁelds in which PHC long has been debated such has
RA48, may assist in PHC for OA by enabling better designs for
tailoring clinical studies in the future.
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